Year Ended December 31,

2024

2023

2022

U.S. dollars in thousands

Commercial Operations Segment Adjusted EBITDA

(5,864)

(20,173)

(16,595)

Research And Development Adjusted EBITDA

(5,129)

(8,165)

(12,420)

Financial income (expenses), net

6,346

11,284

(28,825)

Share-based compensation to employees and service providers

(665)

(1,647)

(5,675)

Depreciation

(588)

(1,445)

(2,136)

Amortization of intangible assets

(31)

(545)

(6,018)

Gain from early termination of lease

22

543

—

Other income (expenses)

(2,359)

44,064

—

Consolidated Comprehensive income (loss)

(8,268)

23,916

(71,669)

Supplementary information on material income or expense items included in the segment results:

Licensing revenues included in the Research And Development Adjusted EBITDA

547

—

2,000

Loss from Global Termination Agreement included in the Commercial Operations Segment, not included in the Adjusted EBITDA

(2,359)

—

Gain from the sale of Movantik®, included in the Commercial Operations Segment, not included in the Adjusted EBITDA

—

44,064

—